Iterum Therapeutics plc (ITRMF) Accounts Payables (2017 - 2025)

Iterum Therapeutics' Accounts Payables history runs 9 years deep, the most recent figure standing at $577000.0 for Q3 2025.

• In Q3 2025, Accounts Payables fell 30.9% year-over-year to $577000.0; the TTM figure through Sep 2025 stood at $577000.0 (down 30.9% YoY), while the FY2024 annual figure was $251000.0, down 94.98% from the prior year.
• Accounts Payables for Q3 2025 stood at $577000.0, down from $1.2 million in the prior quarter.
• The five-year high for Accounts Payables was $5.5 million in Q3 2023, with the low at $251000.0 in Q4 2024.
• The 5-year median for Accounts Payables is $1.2 million (2025), against an average of $1.8 million.
• The sharpest annual moves came in 2023 and 2024: Accounts Payables jumped 372.05% in 2023, then sank 94.98% in 2024.
• Iterum Therapeutics' Accounts Payables stood at $878000.0 in 2021, then jumped by 215.95% to $2.8 million in 2022, then surged by 80.1% to $5.0 million in 2023, then tumbled by 94.98% to $251000.0 in 2024, then surged by 129.88% to $577000.0 in 2025.
• Business Quant data shows ITRMF's Accounts Payables at $577000.0 in Q3 2025, $1.2 million in Q2 2025, and $413000.0 in Q1 2025.